Table 3.
Parameters of bone and mineral metabolism at baseline and final follow-up after 24 weeks in study participants with available values at both study visits
| Baseline | Follow-up (24 weeks) | Treatment effect (95% CI) | p value | |
|---|---|---|---|---|
| 25(OH)D (nmol/L) | ||||
| Vitamin D (n = 79) | 48.8 ± 16.8 | 90.2 ± 20.1 | 33.4 (24.5 to 42.2) | < 0.001 |
| Placebo (n = 41) | 48.8 ± 17.5 | 56.8 ± 29.5 | ||
| PTH (pg/mL)* | ||||
| Vitamin D (n = 81) | 41.9 (34.4–53.8) | 40.6 (32.4–51.1) | − 6.6 (− 11.3 to − 1.9) | 0.004 |
| Placebo (n = 42) | 40.2 (33.0-51.4) | 45.7 (37.6–55.5) | ||
| 1,25(OH)2D (pmol/L) | ||||
| Vitamin D (n = 75) | 114 ± 48 | 141 ± 52 | 27 (8 to 46) | 0.006 |
| Placebo (n = 41) | 110 ± 43 | 113 ± 48 | ||
| Plasma calcium (mmol/L) | ||||
| Vitamin D (n = 79) | 2.35 ± 0.08 | 2.32 ± 0.07 | 0.02 (− 0.003 to 0.05) | 0.081 |
| Placebo (n = 41) | 2.36 ± 0.07 | 2.32 ± 0.07 | ||
Data are shown as means with standard deviation or medians and interquartile range, as appropriate. Treatment effects with 95% confidence interval and p values were calculated by ANCOVA for group differences at follow-up with adjustment for baseline values
1,25(OH)2D 1,25-dihydroxy vitamin D, 25(OH)D 25-hydroxyvitamin D, PTH parathyroid hormone
aSkewed variables for which logarithmic transformed values were used in ANCOVA, but untransformed values are shown in the table